Houston-based Clinical Research Organization (CRO) MedSource is growing its service-offering to include the early stages of clinical development and pipeline planning through Investigational New Drug (IND) submissions. The service will be provided by a new department which will be responsible for delivering a suite of clinical development services to biotech and pharmaceutical companies wishing to organize their pipeline strategy, prioritize indications, and develop strategies that will efficiently advance new drug candidates into the clinic. The enhanced offering establishes MedSource as a partner that can offer its expertise throughout the entire drug development process, in complement to the execution of clinical trials that has been a mainstay for its 20-year history.
Additionally, MedSource is opening a new office in the Cambridge Innovation Center (CIC) in Cambridge, MA. The Scientific Development team will join other cross-functional roles to operate from this new location.
"At this early stage of the process, before human trials can be conducted, many smaller biotechnology organizations must seek financial backing by presenting a 'selling document,' which is a critical step for these programs," Sanchez said. "With our expertise, we can help position a new drug or therapy in the best light, demonstrating how to maximize ROI and capitalize on the core elements of the science to show investors the strength of the asset or program."
By becoming integrated into the process earlier than traditional CROs, MedSource can conduct indication prioritization, data mining, competitor analysis, and establish solid data and analysis to point to the possible pathways for accelerated regulatory opportunities, which is something biotech companies often do not have the resources or time to invest in when developing a clinical plan and pipeline. Presenting this information strategically and validating the clinical development plan can bring a valuable benefit to organizations seeking the financial backing needed to continue clinical trials.
The Boston office brings the total number of MedSource locations to five, globally, and together with the addition of early clinical development support services and the most recent data services acquisition – that incorporated end-to-end clinical biometrics, data management and medical writing in-house – progress isn't slowing down. The company remains on track to continue its positive growth story providing increased value to its clients through a full suite of services and superior clinical offerings.